Under hypoxia tumor microenvironment, colorectal CAFs-secreted TGF-β can promote CSCs maintenance and reduce sensitivity to 5-fluorouracil and oxaliplatin by hypoxia/TGF-β/GLI2 signature [82]. The gene discussed is TGFB1; the disease is neoplasm.